Prasinezumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Prasinezumab Usage And Synthesis

Uses

Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1].

IC 50

α-synuclein Aggregation

References

[1] Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407. DOI:10.3389/fneur.2021.705407

Prasinezumab(1960462-19-4)Related Product Information

• ABAGOVOMAB
• Research Grade Sofituzumab(DHJ31004)
• Vibostolimab
• Mupadolimab
• Trastuzumab
• Bimagrumab
• Alirocumab
• citatuzumab
• VEGFR2 Kinase Inhibitor I
• Blinatumomab